Peng Carol Chiung-Hui, Huai-En Chang Rachel, Pennant Majorie, Huang Huei-Kai, Munir Kashif M
Department of Internal Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, USA.
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
J Endocr Soc. 2019 Nov 16;4(2):bvz008. doi: 10.1210/jendso/bvz008. eCollection 2020 Feb 1.
Painful Hashimoto thyroiditis (pHT) is a rare diagnosis, and optimal treatment remains unclear. To better characterize pHT, PubMed, Embase, Scopus, and Web of Science indexes were searched for case reports or case series reporting pHT, published between 1951 and February 2019. Seventy cases reported in 24 publications were identified. Female predominance (91.4%) and a median age of 39.00 years (interquartile range, 32.50-49.75 years) were observed. Among reported cases, 50.8% had known thyroid disease (including Hashimoto thyroiditis, Graves disease, and seronegative goiters), 83.3% had positive antithyroid peroxidase antibodies, and 71.2% had antithyroglobulin antibodies. Most cases did not have preceding upper respiratory tract symptoms or leukocytosis. Ultrasound features were consistent with Hashimoto thyroiditis. Thyroid function at initial presentation was hypothyroid (35.9%), euthyroid (28.1%), or thyrotoxic (35.9%). Cases evolved into hypothyroidism (55.3%) and euthyroidism (44.7%), whereas none became hyperthyroid after medical treatment. Thyroid size usually decreased after medical treatment. Most cases were empirically treated as subacute thyroiditis with corticosteroids, levothyroxine, or nonsteroidal anti-inflammatory drugs. However, no therapy provided sustained pain resolution. In subgroup analysis, low-dose oral prednisone (<25 mg/d) and intrathyroidal corticosteroid injection showed more favorable outcomes. Total thyroidectomy yielded 100% sustained pain resolution. Diagnosis of pHT is based on clinical evidence of Hashimoto thyroiditis and recurrent thyroid pain after medical treatment. The reference standard of diagnosis is pathology. Total thyroidectomy or intrathyroidal glucocorticoid injection should be considered if low-dose oral prednisone fails to achieve pain control.
疼痛性桥本甲状腺炎(pHT)是一种罕见的诊断,最佳治疗方法仍不明确。为了更好地描述pHT,我们在PubMed、Embase、Scopus和Web of Science数据库中检索了1951年至2019年2月期间发表的报告pHT的病例报告或病例系列。共识别出24篇出版物中报告的70例病例。观察到女性占优势(91.4%),中位年龄为39.00岁(四分位间距,32.50 - 49.75岁)。在报告的病例中,50.8%有已知的甲状腺疾病(包括桥本甲状腺炎、格雷夫斯病和血清阴性甲状腺肿),83.3%抗甲状腺过氧化物酶抗体呈阳性,71.2%抗甲状腺球蛋白抗体呈阳性。大多数病例没有前驱上呼吸道症状或白细胞增多。超声特征与桥本甲状腺炎一致。初次就诊时甲状腺功能为甲状腺功能减退(35.9%)、甲状腺功能正常(28.1%)或甲状腺毒症(35.9%)。病例发展为甲状腺功能减退(55.3%)和甲状腺功能正常(44.7%),而药物治疗后无一例变为甲状腺功能亢进。药物治疗后甲状腺大小通常会减小。大多数病例经验性地用皮质类固醇、左甲状腺素或非甾体抗炎药治疗亚急性甲状腺炎。然而,没有一种治疗方法能持续缓解疼痛。在亚组分析中,低剂量口服泼尼松(<25 mg/d)和甲状腺内皮质类固醇注射显示出更有利的结果。全甲状腺切除术可使疼痛100%持续缓解。pHT的诊断基于桥本甲状腺炎的临床证据和药物治疗后反复出现的甲状腺疼痛。诊断的参考标准是病理学。如果低剂量口服泼尼松未能实现疼痛控制,应考虑全甲状腺切除术或甲状腺内糖皮质激素注射。